FGEN
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
225
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
emptyResult
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Recently from Cashu
It seems there was an error, and I don't have the content you'd like me to summarize. Please provide the text, and I'll be happy to help!
Please provide the content you would like me to summarize.
FibroGen's Roxadustat Shows Promise in Chronic Kidney Disease Anemia Treatment
FibroGen Advances in Chronic Kidney Disease Treatment FibroGen, a biotechnology company focused on developing and commercializing innovative therapeutics, makes significant strides in the treatment of…
FibroGen's Roxadustat Revolutionizes Anemia Treatment for Chronic Kidney Disease Patients
FibroGen's Innovative Approach to Anemia Treatment Enhances Patient Care FibroGen, a biotechnology company focused on developing innovative therapies for serious diseases, continues to make strides in…
FibroGen's Roxadustat Shows Promise in Anemia Treatment for Chronic Kidney Disease
FibroGen Advances in Anemia Treatment with Promising Data FibroGen Inc. makes significant strides in the development of its anemia treatment, demonstrating a robust safety and efficacy profile in rece…